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1. INTRODUCTION
 
1.1  HIV Infection and AIDS Worldwide 
Human Immunodeficiency Virus (HIV) disease is a 
chronic infectious disease caused by the HIV, which is 
characterized by spectrum starting from primary 
infection, with or without the acute syndrome, followed 
by relatively long period of asymptomatic stage after 
which in most patient‟s progress to advanced and life 
threatening disease Acquired Immune Deficiency 
Syndrome (AIDS).
1
 
HIV/AIDS is a global pandemic, with cases reported 
from virtually every country. At the end of 2011, an 
estimated 35.9 million individuals were living with HIV 
infection according to the Joint United Nations 
Programmed on HIV/AIDS (UNAIDS). More than 95% 
of people living with HIV/AIDS (PLWHA) reside in low 
and middle income countries; 50% are female, and 2.5 
million are children <15 years.
2
 In sub-Saharan Africa, 
there has been a dramatic increase in the number of 
HIV/AIDS patients, nearly two-thirds of PLWHA live in 
sub-Saharan Africa.
3 
Ethiopia is among the country most affected by the HIV 
epidemic with an estimated adult prevalence of 1.5 %, 
has large number of people living with HIV 
(approximately 800,000); and about 1 million AIDS 
orphans. 
4
 
The global distribution of the estimated number of 
PLWHA; i.e., the global prevalence has increased 
approximately fourfold since 1990, reflecting the 
combined effects of continued high rates of new HIV 
infections and the beneficial (life-prolonging) impact of 
antiretroviral therapy.
1
 
1.2  Antiretroviral Therapy (ART)   
ART is the administration of at least three different 
medications known as Anti-Retro Viral drugs (ARV) in 
order to suppress the replication of the HIV. Treatment 
with these combinations of drugs is also known as 
Highly Active Antiretroviral Therapy (HAART). ART is 
not a cure. It must be taken for life and is costly. ART 
changes a uniformly fatal disease to a manageable 
chronic illness. Successful use of ART suppresses HIV 
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viral replication, consequently slowing down disease 
progression, improving immunity and delaying mortality. 
Even if ART is not a cure, it prolongs and enhances the 
quality of life of PLWHA. Once ART is started, it has to 
be taken for life with better than 95% adherence.
4
     
ART has shown to delay progression to AIDS, resulting 
in a greater and more sustained virologic and 
immunologic response and improve survival. In sub-
Saharan Africa, there has been a dramatic increase in the 
number of HIV/AIDS patients on ART from just 100,000 
persons in 2003 to 3.9 million in 2009 involving close to 
40% of those in need of the treatment.
3
 
Two sub-Saharan Africa countries, Botswana and 
Rwanda, have achieved universal access target 
(treatment coverage of 80% or more of patients in need) 
at the end of 2009 while countries such as Ethiopia, 
Zambia, Namibia, and Senegal are moving closer to the 
same target having covered 50–80% of patients in need 
of treatment .
5
 
1.3 Anti Retroviral Drugs (ARV)  
There are currently three major classes of ARV drugs: 
nucleoside or nucleotide analogue reverse transcriptase 
inhibitors (NRTIs), non-nucleoside reverse transcriptase 
inhibitors (NNRTIs) and protease inhibitors (PIs).
 4 
 NRTIs include the thymidine analogs stavudine and 
zidovudin; the deoxycytidine analogs emtricitabine and 
lamivudine; the deoxyguanosine analog abacavir sulfate; 
and the deoxyadenosine analogs of which didanosine is 
an inosine derivative and tenofovir disoproxil fumarate is 
a deoxyadenosine-monophosphate nucleotide analog (a 
nucleotide is a nucleoside with one or more phosphates). 
NNRTIs are a chemically heterogeneous group of agents 
that bind noncompetitively to reverse transcriptase 
adjacent to the catalytic site. Available NNRTIs include 
efavirenz, delavirdine, nevirapine and etravirine. PIs 
include amprenavir and its prodrug fosamprenavir, 
atazanavir, darunavir, indinavir, lopinavir, nelfinavir, 
ritonavir, saquinavir, and tipranavir. PIs competitively 
inhibit the cleavage of the gag-pol polyprotein, which is 
a crucial step in the viral maturation process, thereby 
resulting in the production of immature, noninfectious 
virions.
6 
Advance in retroviral medication result in precipitous 
declines in HIV associated morbidity and mortality. 
ARV medications have transformed HIV to a chronic 
condition requiring life-long treatment. The effects of 
ARV medications on prolonging life and preventing 
opportunistic infections have been well documented, and 
there is evidence that the resultant lower viral loads are 
associated with lower risks of HIV transmission to both 
unborn children and sexual partners.
5 
   
1.4 Adherence to ARV drugs  
Adherence is the act or quality of sticking to something 
or to adhere to something. Adherence to medication is 
the degree of concurrence between client‟s behaviors 
(taking medication, sticking to diet, taking the right dose 
and at the right time) and following medical advice on 
medication regimen. The term „medication adherence‟ in 
HIV/AIDS care specifically refers to the ability of the 
person living with HIV/AIDS to be involved in choosing, 
starting, managing  and maintaining a given therapeutic 
combination medication regimen to control viral (HIV) 
replication and improve immune function.
4 
 It is act or quality of sticking to something, steady 
devotion, the act of adhering and best achieved through a 
collaborative process that facilitates acceptance and 
integration of medication regimen into an individual's 
daily life.
5
  
Non adherence may mean not taking medication  at all, 
taking  reduced  amounts, taking  more medication  than  
prescribed,  not  taking  doses  at prescribed frequencies 
or intervals or not matching medication to  food  
requirements  and  self  initiated holidays.  Factors  
associated  with  non  adherence include  lower  income,  
lower  education,  substance use, higher  dose  frequency  
and  fewer  adherence  aids such  as  pillboxes  and  
timers.  The frequency  and severity of side effects 
conflicts with daily routine, dietary recommendations, 
frequency of medication dosages,  number  o f   
medication   dosages, psychological  factors  such  as  
stress,  anger,  or  denial and  physical  consideration  
such  as  fatigue  and  sleep.
7 
Adherence to HIV treatment is critical to the success of 
improving the quality of life and survival of people with 
HIV/AIDS. Interventions and services should be 
multifaceted, tailored for each patient, and delivered 
through a multidisciplinary team approach that includes 
the patient in collaborative treatment planning.
8
  
The 2
nd
 strategies predictors of progression on AIDS and 
death after CD4 count is adherence to therapy. A 
significant association exists between adherence and 
viral load suppression in which non adherence leads to 
the developments of antiretroviral resistant virus because 
full and durable viral suppression necessitates nearly 
perfect adherence stressing and promoting compliance 
will help to insure maximum benefit from HAART and 
reduce the development of resistance.
8
     
Efficacy of ARV drugs in HIV/AIDS is showing 
inhibition of viral replication and reduction of viral load 
at a point where viral particle are undetectable in the 
blood of infected individuals. According to recent 
studies, ART regimens require 70–90% adherence in 
order to be effective. However, sustaining adherence to 
ART over the long term requires accurate and consistent 
monitoring, and this is a particular challenge for 
countries in sub-Saharan Africa.
 5 
 It is further challenged by various social and clinical 
obstacles where inadequate suppression of viral 
replication by ART are resulting due to poor adherence 
to therapy, low potency of the antiretroviral regimen, 
viral resistance to antiretroviral medications, and 
pharmacokinetic interactions causing inadequate drug 
delivery. The transmissibility of the antiretroviral 
resistant viruses from person to person further 
compounds the problem as a clinical and public health 
challenge.
5 
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1.5. Adherence Measurement Strategies 
The measurement of medication adherence is a difficult 
both in clinical care and research settings. Quantifying 
the levels and types of medication adherence involved 
patient care has been the focus of many studies resulting 
in the identification of multiple direct and indirect 
measures. Given the significance of viewing medication 
initiation and continuation as a process involving stages 
of change, measurement tools have been developed to 
attempt „matching‟ communication strategies to 
readiness for treatment. Some of the most recent work in 
the area of antiretroviral medication adherence 
measurement has supported the independent association 
of patient and provider reported adherence with multiple 
variables that influence adherence; accordingly areas to 
be explored more fully include incorporating a 
combination of patient and provider reporting and 
pharmacy refill data. A single isolated method of 
adherence assessment seems to be inadequate and 
impractical. Use of more than one ART adherence 
measures to capture more accurate information to 
determine adherence levels have been recommended. 
There may be no gold standard with which to measure 
adherence, there are several strategies available, each 
with its respective strengths and weaknesses.
9
 
Clinical studies have employed medication event 
monitoring System (MEMS), pharmacy refill data, 
providers‟ estimates and directly observed therapy 
(DOT) or directly administered ART (DART) either 
alone or in combination to measure ART adherence.  
After being on ART for some time, the patient gets 
habituated to pill count exercise and manages to bring 
exact number of pills to the clinic. He/ she may either be 
throwing pills every day or removing them from the 
bottles just before visiting the clinic. It is obvious that 
being a patient enabled issue; any adherence measure 
related to patient (report/ pill count) has its own 
disadvantages owing to the psychosocial need of social 
desirability or merely to avoid reprimand from health 
care provider.
10
 
1.5.1 Self-reports: Three main types of self-report 
adherence measures have been used include surveys, 
interviews and diaries.  Each is relatively easy to use and 
inexpensive, although data    from several studies suggest 
that self-reports tend to overestimate actual adherence.  
One study that explored adherence rates in hypertensive 
patients found that 67% overestimated their adherence 
when self-reports from diaries were compared with data 
from the Medication Event Monitoring System (MEMS) 
caps.
8, 9
  
Among investigators studying HAART adherence, there 
is agreement that self-report surveys that ask about 
missed doses within a very short time frame, i.e. within 
one to four days, are more valid and reliable than surveys 
that ask the respondent to remember a week or more 
ago.
9 
1.5.2 Clinician Assessments: There appears to be few 
HIV-related studies that have assessed the accuracy of 
clinician assessments of actual or potential adherence of 
their patients.  Preliminary data presented in abstract 
form suggest that physicians overestimate patient 
adherence to HIV medication.
10
 
1.5.3 Pill Counts: One strategy to evaluate adherence is 
to view the actual pill container and calculate how many 
pills should be left, given the date of the inspection, 
dosing and last refill.  Because pill counts often occur in 
provider offices, clients are able to manipulate the 
number of pills remaining prior to the visit. Unscheduled 
home visits to conduct pill counts have the potential to 
be more accurate.  Regardless of where the count 
actually takes place, reported that weekly pill counts 
demonstrated marked intersubject and intrasubject 
variability, obscured by long-term averages.
8,10
 
1.5.4 Prescription Refills:  Prescription refills may be a 
mechanism for assessing adherence to antiretroviral 
medications.  Theoretically, pharmacists could work 
closely with health care providers and patients, 
informing both parties when medications are not being 
filled as directed. Unfortunately, such a close working 
relationship rarely exists in practice and patients may fill 
their prescriptions at different pharmacies.  Although 
prescription refills could be monitored by the payer, 
insurance status often changes and thus, the payer 
source. Gaining access to pharmacy records remains 
difficult and the relationship between refills and actual 
ingestion of medications is not always clear.
9
 
1.5.5 Biological Assays: Blood or urine biological assays 
can be used to measure adherence to treatment.  Two 
main types of assays are available, but their use in 
monitoring adherence is controversial.  Marker assays 
are based on materials that can be added to a drug and 
are easily detected, typically in the urine.  Direct assays 
refer to testing for the presence of the medication itself in 
the blood or urine.  Given the half-life of most 
medications, direct and indirect assays have the capacity 
to only measure adherence for the most recent doses 
taken, and not over longer periods.  Biological assays to 
measure levels of antiretroviral medications and their 
metabolites are not commercially available at this time, 
thus further limiting this as a viable strategy to monitor 
adherence. Studies assessing composite „scores‟ derived 
from self-administered questionnaires and plasma levels 
of PI have supported the value of plasma PI levels as an 
objective marker of antiretroviral therapy.
8, 10
 
1.5.6 Medication Event Monitoring System: MEMS 
bottle caps are thought by some to provide a valid and 
reliable measure of medication adherence.
 
These devices 
are special bottle caps that contain computer chips that fit 
on standard medication containers. The microchip stores 
the date and time each time the medication container is 
opened and closed.  A long-life battery that cannot be 
switched on or off is also included. Data are retrieved by 
downloading the information from the cap device to a 
computer, which provides a spreadsheet display of an 
overview of individual adherence.
9, 11
 
 1.5.7 Adherence to HIV Treatment Regimens: This 
strategy may not work well when a large number of pills 
and complex treatment regimens are prescribed.  In a 
sample of hypertensive patients, compared pill counts 
and MEMS data and found that each method identified 
different patients as being non-compliant. Investigators 
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at the University of California at San Francisco note that 
MEMS data can be scored only as “opened/closed” as 
many patients take out their entire supply of pills for the 
day and place them in their pockets instead of carrying 
around the medication bottles.
9,11
 
1.6. Factors Associated with Adherence and Non 
adherence
 
Adherence to ART can be influenced by characteristics 
of the patient, the regimen, the clinical setting, and the 
provider/patient relationship. To assure adherence, it is 
critical that the patient receive and understand 
information about HIV disease, the goal of therapy, and 
the specific regimen prescribed.
12
 
1.6.1 Patient factors  
Patient factors that have been studied include; 
sociodemographic factors –such as gender, ethnicity, 
age, employment, income, education and literacy: and 
psychosocial factors such as active drug and alcohol use, 
degree of social support, social stability, depression and 
other psychiatric illness. Sociodemographic factors do 
not seem to adherence behavior, although some studies 
have found that male sex, white ethnicity, older age 
higher income and higher education correlate with better 
adherence.
11,12,13 
On other hand numbers of psychosocial factors have 
been found to strongly influence adherence; depression, 
psychiatric illness and active alcohol or drug use prevent 
patients from adhering to treatment. Social support helps 
patients to adhere better. A patient knowledge of his/her 
medication regimen and a patients understanding of the 
relationship between non adherence and build up of 
resistance to medication also predict better adherence. A 
patient belief and confidence in therapy.
13
  
1.6.2 Medication factors 
HAART consist of complex regimen that include up 20 
pills a day with multiple dosing throughout a day   and 
specific food and fluid related instructions. These are 
often difficult to follow for patient and contribute poor 
adherence. The higher the pill burden the lower is the 
adherence. A patient who reported experiencing "severe" 
side-effects, including hallucinations and insomnia, 
which affected his/her ability to work, discontinued ART 
in the early stages of treatment.
14 
ARV medication often have side effect, some of which 
are temporary (diarrhea, nausea and vomiting) while 
others may permanent or longer lasting (peripheral 
neuropathy, physical change in body appearance, 
lipoatrophy, lipodystrophy and metabolic change). 
Studies have shown that when patients experience side 
effect they tend to stop treatment or take it irregularly. 
12, 
14
   
1.6.3 Patient-provider’s relationship 
The patient–provider relationship play an important role 
in improving adherence to prescribed medication in 
chronic disease. It is believed to motivating factor for 
adherence to HAART. Trust and confidence in provider 
has been found to influence adherence positively. 
Communication barriers were thought to contribute to 
poor adherence. Providers felt that this primarily affected 
patients who spoke languages different from those of 
their providers.
14 
1.6.4 Disease characteristics 
 Prior opportunistic infections contribute to increased 
adherence. Patients who have had serious OI may 
perceive their illness to be severe and adhere better to 
their treatment.  Feeling well after taking treatment was 
reported as both barriers to, and facilitators of 
adherence.
7
 
1.6.5 Clinical setting/health system 
Aspects of clinical setting may associated with improved 
adherence. Different determinants of adherence are 
depicted in Figure 1. A friendly and supportive and non 
judgmental attitude of health care providers, convenient 
appointment scheduling and confidentiality contributes 
to better adherence. Most patients interviewed felt that 
clinic waiting times were too long. This contributed to 
their dissatisfaction with clinic services and made them 
more likely to stop coming to the clinic to pick up their 
medications.
16 
The major factors associated with 
adherence and non adherence are mentioned in Table 1. 
 Again, despite an association being intuitive, clinical 
studies addressing the relationship between the clinical 
setting and adherence behavior are very limited. 
Dissatisfaction with prior experience in the health care 
system has been associated with non adherence.
17
 
 
Figure 1:   Determinants of adherence
15 
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Table 1: Factors associated with adherence and non adherence
14
. 
 
 
2. SIGNIFICANCES OF THE LITERATURE 
REVIEW 
As more people gain access to ART, new initiatives are n
eeded to help ensure  that patients adhere to treatment. 
The maintenance of viral suppression requires maximum 
adherence (at least 95%) to ART. Insufficient adherence  
to ARVs may result in treatment failure and the emergen
ce of drug resistant strains of HIV  and require a change  
to  second‐line treatment regimens, thereby greatly 
increasing treatment costs. This literature review helps to 
know factors affecting adherence, trategies to measure 
adherence to ART and research recently (2008-2013) 
done on intervention to improve ARV adherence 
(adherence improving tools and strategies). 
3. OBJECTIVE OF THE REVIEW:  
The objective of this review was to assess the latest 
literatures regarding interventions to improve 
antiretroviral medication adherence.  
4. METHODS 
This literature review was obtained from electronic 
search on pubmed, AIDS lines, MEDILINE, PyschInfo 
and also search conducted on individual journals and 
manuals. The search words or phrases were adherence, 
antiretroviral medication and intervention to improve 
adherence to antiretroviral medication. Each manuscript 
was analyzed according to all characteristics: purpose, 
conceptual framework, research question/hypothesis, 
variables, sample measures/instruments, 
method/statistical procedures, results, interpretation, 
recommendation and implication for health care. 
Qualitative and quantitative studies reporting original 
data on intervention to improve ARV medication 
adherence among HIV infected patients from 2008-2013 
were included. 
5. INTERVENTION TO IMPROVE ADHERENCE 
TO ARV DRUGS 
Increasing recognition of medication adherence as a 
crucial factor in treatment outcomes has sparked a 
number of recent studies investigating methods to 
support and improve adherence. Continuous monitoring 
of both adherence and correlating it with clinical 
outcomes will create an interactive feedback mechanism 
that could lead to optimal clinical states and improved 
quality of life for patients. There are needs for further 
research and development in the area of ART adherence, 
adherence support, and patient behavior
14 
Diagnosing and treating health problems such as 
depression, reducing substance abuse, improving 
patient‟s and providers relationship, counseling and 
enhancing family, and community support mechanisms 
are shown to improve adherence, as well as intervening 
on modifiable barriers to adherence before starting ART. 
A meta-analysis by Amico and colleagues indicated that 
adherence interventions may be efficacious when 
targeted at individuals who are identified or anticipated 
to have poor adherence.
18 
The few investigations of interventions indicate that 
electronic reminders, pill organizers, MEMS to record 
dosing behavior, use of internet, educations services, use 
of phones, and so forth can also enhance adherence. 
However, most of these technologies have not had 
thorough scientific evaluation and their efficacy and cost 
effectiveness may not be as high as expectations. Cell 
Demographic Factors 
Individual patient attributes   
Associated with adherence: Being in school Inconsistent or no association with 
adherence or nonadherence: Age, sex, race 
Socioeconomic status ssociated with nonadherence: Housing instability 
Substance use and coping 
skills 
Associated with adherence: Less alcohol use, less recent drug use (past 3 months)  
Associated with nonadherence: Depression-withdrawal coping style or self-destructive 
escape coping style, younger age of first marijuana use 
Psychologic/ 
Developmental 
Associated with adherence: Self-efficacy, higher life satisfaction on the quality-of-life 
scale, lower levels of psychologic distress, concrete rather than abstract reasoning 
skills, belief that medication would “most definitely” improve their quality of life. 
 Associated with nonadherence: Depressive symptoms, symptoms of anxiety, sexual 
abuse under age 12 years, prior suicide attempt(s) Inconsistent or no association with 
adherence or nonadherence: Youthful feelings of  “invulnerability” 
  
Sexual risk Associated with adherence: Less likely to have bartered sex during their lifetime, more 
likely to have used condoms with recent sex partners, less likely to have had a sexually 
transmitted disease since learning their serostatus 
Disease Factors Associated with adherence: Reduced viral load,  CD4+ level ≥ 500 cells/μL 
Associated with nonadherence: Detectable viral load,later disease stage 
Medication Factors Associated with adherence: Fewer drugs prescribed, medication-related adverse effects 
(both physical and psychologic) 
Associated with nonadherence: Length of treatment with antiretroviral medications 
self-assessment of adherence by patient 
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phone message reminders and web-based interventions 
require patient resources and literacy which could create 
obstacles to their applicability in developing country.
12 
A recent systematic review published by the Cochrane 
Database of Systematic Reviews reached similar 
conclusions. It cited diverse methodological problems 
and issues of study quality, among others as problems 
underlying the scant evidence on adherence 
improvement interventions and called for standardized 
and methodologically rigorous trials of interventions to 
improve and measure adherence to antiretroviral 
treatment.
16 
5.1. Adherence improving tools 
5.1.1. Telephone reminders and calls 
Telephone reminders are being tried out in some studies 
on adherence. There are several limitations to its uses: it 
is labour intensive for staff, patients must have telephone 
at all time and cost issue. With over 230 million cell 
phones in use and 7 billion text messages sent every 
month in the United States, text messaging or short 
message service (SMS) has become a common mode of 
communication among youth, including those who are 
economically disadvantaged. This low-cost, convenient 
technology has provided benefit in a variety of health 
care settings and has been shown to be an effective tool 
for behavior change. Mobile phones have been shown to 
improve chronic disease management in developed 
countries and have been proposed as a potential strategy 
to support ART adherence in developing countries.
15
   
Reminder devices, however, have shown mixed results 
and few data are available for resource-limited settings. 
Encouragingly, a study conducted in Mombasa, Kenya, 
found that alarm devices signiﬁcantly improved non-
ART medication adherence rates among women 
attending sexually transmitted disease and family 
planning clinics.
19 
 Evidence suggests that text messaging interventions may 
increase medication adherence among children and 
adolescents living with other chronic diseases such as 
asthma and diabetes (improve). Several studies have 
used both daily and weekly unidirectional, standardized 
SMS medication reminders for HIV-positive individuals 
in low-resource settings, but no published data have 
evaluated SMS medication reminders among youth 
living with HIV/AIDS in the United States. In particular, 
text messaging is well suited as a vehicle for ecological 
momentary interventions; that is, mobile technology can 
provide treatment to patients in real time and in their 
natural environments. Additionally, recent reviews of the 
literature on text messaging interventions for health 
behavior change have identified key characteristics for 
success; including interactivity and tailoring of 
messages, which were associated with higher retention 
rates in multiple studies.
16 
Pilot study conducted on youth in the Children‟s 
Hospital of Philadelphia on 25 youth enrolled over 6 
month period 21 youth (84%) complete the study. The 
intervention was rated highly on indicators of 
satisfaction: at the 24-week follow-up, 17 of 21 (81%) 
participants who completed the study said they would 
like to continue to receive text messages after the end of 
the study, and 20 of 21 (95%) participants indicated that 
the text messages helped them “very much” to miss 
fewer doses of medication. During the study period 
15,387 messages were sent and received through the 
Intelecare platform. Of the outgoing messages sent 1167 
messages were not delivered and 14,220 messages were 
successfully sent. Of the 7110 messages requesting a 
response, 3414 (48.02%) text message replies were sent 
by participants indicating whether they took their 
medications.
20
 
 A randomized controlled trial of four SMS reminder 
intervention with 48weeks of follow up on 735 patients 
older than 18years participant‟ conducted in Kenya. 
They had been receiving weekly SMS reminder.  These 
weekly reminders were also effective at reducing the 
frequency of treatment interruptions, which have been 
shown to be an important cause of treatment resistant 
failure in resource-limited setting. Like other successful 
adherence interventions, the intervention was effective in 
part by preventing the decline in adherence seen in the 
control group from 60 to 46% achieving 90% adherence 
over 48 weeks. Despite SMS outages, phone loss, and a 
rural population, these results suggest that simple SMS 
interventions could be an important strategy to sustaining 
optimal ART response. Preventing adherence-related 
treatment failure is especially important in resource-
limited settings wherein second-line therapy is up to 17-
fold more expensive than 1
st
 line therapy and often 
unavailable. On this study adding words of 
encouragement in the longer text message reminders was 
not more effective than either a short reminder or no 
reminder.
21 
Although previous studies have shown beneﬁt with 
individualized adherence tools, future cell phone based 
interventions should investigate how message form and 
content inﬂuences HIV and other chronic disease-related 
behavior. Message content must also take into account 
the common practice of shared mobile phone use and the 
potential that individuals will change phones numbers. It 
is also interesting to note that weekly reminders 
improved adherence, whereas daily reminders did not.
21 
Further research is needed to distinguish the mechanisms 
as to why the weekly messages were most efficacious. In 
a sub-study of a larger multicenter study 282 patients 
were studied with approximately 50% receiving „usual‟ 
approach to medication adherence counseling and 50% 
receiving additional „intensive‟ telephone counseling (16 
calls over 96 wks). No increased level of adherence or 
virologic improvement was noted in those individuals 
receiving more intensive telephone counseling.  It should 
be noted that other trials have demonstrated some 
increased efficacy with „telephone‟ counseling as yet 
another component of overall care.
21 
Lima and colleagues  conducted a study to examine the 
effect of a telephone consultation service (Warm line) on 
the clinical outcomes of HIV-infected patients who were 
prescribed antiretroviral salvage therapy regimens and 
had a viral load at least 1,000copies/ml at the baseline 
assessment. The study found that participants who 
received the Warm line consultation demonstrated 
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significant declines in viral load and increases in CD4 
cell counts at 3-and 6-month follow ups compared with 
the baseline values.
8
  
Reynolds using a multisite RCT, tested if a standard 
clinic-based patient education with structured and 
proactive telephone calls delivered over a 16-week 
period improved treatment adherence better than 
standard clinic-based patient education. Telephone 
support participants self-reported higher adherence rates 
and had lower risk for virologic failure at the final 
endpoint compared to controls. The finding suggested 
that telephone delivered interventions can be an effective 
means to reinforce medication adherence. Because 
numerous studies demonstrated the effectiveness of 
telephone-based interventions, the current study used the 
telephone as a vehicle to deliver MI for 54 antiretroviral 
adherence improvement interventions in HIV-infected 
persons living in rural areas.  The current study 
examined the effectiveness of a single session of 
telephone administered MI to improve medication 
adherence in rural persons living with HIV/AIDS.
22
  
Self-reported data assessing dose adherence and schedule 
adherence were the primary outcome measures and were 
assessed through self-administered medication diaries. 
Participants completed two medication diaries over the 
course of 5 weeks. A two-week adherence diary reported 
on adherence prior to the intervention (baseline 
adherence at week 1 and week 2).  A three-week 
medication diary reported on their medication adherence 
during the week of the intervention (week 3) and for two 
weeks following the intervention (post-intervention 
adherence at week 4 and week 5). Changes in self-
reported medication adherence in intervention 
participants were compared to those reported by 
participants assigned to a self-monitoring comparison 
condition. The current study tested the hypothesis that 
compared to control participants; adherence intervention 
participants would report greater increases in self-
reported rates of medication adherence from baseline to 
post-intervention.
22 
A randomized controlled trail conducted in the three 
largest hospitals in China. In this study adherence was 
measured by self completed questionnaires. Outcome 
was assessed at day 15 at 1, 2 and 3 month after start of 
treatment for treatment naïve and at 3 month after study 
enrollment. A total of 103 treatment naïve and 93 
treatment experienced HIV/AIDS patients show that 
phone call intervention could maintain high self reported 
adherence among both treatment naïve and treatment 
experienced patients. After 3 month significant QOL 
improvement were observed in domain of physical health 
and levels of independence.
23
  
5.2 Strategies to improve ARV medication adherence 
5.2.1 Counseling 
Counseling forms the main stay of any treatment 
program. Counseling aims to improve patients‟ 
knowledge about the disease and knowledge about the 
medication and side effects. Counseling helps patient to 
set goals, to develop positive belief and to increase self 
efficacy in addition to counseling patient often need 
other forms of support to able to adhere to treatment.
15 
Motivational interviewing (MI) is a client centered 
counseling method that helps clients resolve ambivalence 
toward and build motivation for behavior change. MI 
counseling has been successful in changing many health 
behaviors including substance use, fruit and vegetable 
intake, and physical activity. More recently MI has been 
used with HIV positive persons to address substance use, 
medication adherence, and safer sex preventive 
behaviors. MI promotes both adherence to medication 
and reduction of risk of HIV transmission.
24 
On study conducted on HIV infected women for 2weeks 
have higher mean adherence rates: report more frequent 
mean use of risk reduction behavior: have higher mean 
CD4 lymphocytes count and lower HIV viral load levels 
as measured by chart reviews of 3
rd
, 6
th
 and 9
th
 month. 
Patient education involves dedicated time with patients 
to plan for and support medication adherence. The nature 
and frequency of these interventions vary, but those that 
appear effective are characterized by an initial 
educational session including individualized 
collaborative medication planning with follow-up 
sessions maintained regularly over the course of 
treatment.
24 
A prototype for such an intervention derives from a 
randomized controlled trial (RCT) of 116 individuals 
initiating their first or second regimen of ART in the 
Netherlands. The intervention group received an 
individualized educational counseling session at baseline 
and at each follow-up visit (0, 4, 24, and 48 weeks) 
designed to increase knowledge and "self-efficacy" 
regarding treatment adherence. Specifically, information 
was provided about HIV and its treatment as well as the 
relevance of adherence in clinical outcomes and 
preventing resistance. In addition, a personalized dosing 
schedule was developed with the patient and plans about 
how to manage side effects were made. During follow-up 
visits, strategies for solving any encountered problems 
were developed. The most common strategies were to 
design a new drug-dosing schedule, to develop habits 
that make remembering doses easier, and to provide 
additional skills to manage mild side effects.
25
 
The control group received standard-of-care clinical 
follow-up. At week 48, 94% in the intervention group vs 
69% of those in the control group achieved >95% self-
reported adherence; 89% of the intervention group vs 
66% of the control had HIV viral loads <400 copies/ml 
The intervention was found to prevent the decline in 
adherence commonly seen over time. Both groups started 
with good adherence, and the intervention helped 
maintain it, although adherence in the control group 
progressively worsened.
25 
A randomized controlled trial involving 170 Spanish 
patients on stable ART found a similar effect. The 
intervention was a pharmacist-led individualized 
education and supportive counseling session at baseline 
with follow-up telephone sessions focusing on adapting 
medication scheduling to the patient's lifestyle. After 24 
weeks, 76% of intervention group vs 52.5% in the 
control group had >90% self-reported adherence and 
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there was a small trend in the intervention group towards 
improved virologic suppression.
26 
Other randomized controlled trials in Europe and the 
United States have confirmed that dedicated time with 
patients to plan for and support medication adherence 
leads to improved adherence and virologic suppression. 
The importance of maintaining this support over time is 
further illustrated by an uncontrolled study that found a 
significant improvement in adherence over a 4-week 
study period with an intervention based upon ongoing 
education and financial rewards for good adherence. 
However, 4 weeks after the intervention was 
discontinued, adherence in the intervention group 
returned to baseline levels.
27
 
On the other hand, in a study to assess the impact of 4 
weekly educational sessions in 196 HIV-positive patients 
belonging to minority groups in the United States, at no 
point during the 24-week follow-up did the intervention 
and control groups differ in terms of MEMS adherence, 
viral load, or CD4 count. Therefore, it remains unknown 
what constitutes an effective educational intervention 
and for whom it may work.
28
 
5.2.2 Directly Observed Therapy (DOT) 
 DOT has been identified as a possible means of helping 
patients with difficulties adhering to ART. DOT is an 
intensive program in which patients take medication 
under supervision of adherence staff. In TB, DOT is 
more regimented and provides a tighter monitoring to 
medication in take  in case of ART, it is not practical to 
observe all doses as most HAART regimen have 
multiple doses and treatment is lifelong. Therefore, only 
some doses are observed for a fixed period of time (few 
months) this is called modified DOT or DAART.
17 
 DAART can be done at the health center, in community-
based organization or even at patients home. It is used as 
behavioral intervention that helps patient to develop 
understanding of the treatment, to develop good 
treatment taking behavior, to receive support during 1
st
 
few weeks of ART when patient have short term side 
effect and to develop a trusting relationship with 
provider. Due to evident difficulties with medication 
adherence, DOT in HIV has been evaluated in a number 
of recent studies in the developed and developing world.
9   
 
ARV had been provided in the context of an established 
DOT program for TB. DOT is feasible and can improve 
clinical outcomes. However, DOT is expensive, labor 
intensive, and potentially perceived as intrusive. It 
remains unclear which populations of patients warrant 
DOT. It is important to recognize the myriad differences 
between TB and HIV prior to extrapolating the 
experience of DOT from one disease to the other. Care 
should be taken to ensure that DOT programs in HIV 
care remain optional and voluntary unless an 
unequivocal public health benefit can be established in 
the particular population of patients in question.
29
 
One study compared 50 incarcerated participants who 
received their initial ART through DOT with 50 patients 
initiating ART at an outpatient clinic who monitored 
their own medication. Those who received DOT had a 
significantly higher chance at any point in the study of 
achieving an undetectable viral load. For example, after 
48 weeks, 100% of the DOT group had viral loads <400 
copies/mL compared with only 68% of the self-
monitored patients. 
30
 
The first randomized controlled trial of community-
based DOT followed 112 HIV-positive, actively drug-
using individuals for 6 months. Those in the intervention 
group received all of their medication each day in a 
blister pack from multidisciplinary personnel.  For those 
on a once-daily regimen, all doses were directly 
observed. Those on a twice-daily regimen received 
modified DOT (DAART); 1 dose was observed and the 
other packet of medication was dispensed to the patient. 
Those in the control group received standard-of-care 
follow-up. After 6 months, compared with those in the 
control group, the patients receiving DOT had significant 
improvements in 3-day self-reported medication 
adherence (+32% vs +8%), 6-month median CD4 count 
(+151 cells/µL vs +20 cells/µL), and 6-month median 
log reduction of viral load (-2.01 copies/mL vs -0.41 
copies/mL).
31
 
A prospective study of m-DOT in a methadone clinic 
provided m-DOT (witnessed morning doses and 
prepackaged evening doses) for 12 months to 50 HIV-
infected drug users (DUs).Their outcomes were 
compared with those for 2 groups of control patients: 90 
matched patients from the same methadone clinic (DU 
controls), and 146 patients without a history of drug use 
(non-DU controls). At 6 and 12 months, m-DOT patients 
(DUs) were significantly more likely to achieve full viral 
suppression (<50 copies/mL) than were DU controls and 
were somewhat more likely to achieve full viral 
suppression than were non-DU controls. Median 
increases in CD4 counts at 12 months, however, were 
similar in all groups.
17
  
DOT also has been studied in pregnant women thought 
to be at high risk for nonadherence and consequent 
mother-to-child transmission. Eight HIV-infected 
pregnant patients who were hospitalized for DOT during 
their third trimester were identified by chart review. 
Their outcomes were compared with those of 32 
controls. The main outcome measure was success of 
therapeutic goals, defined as: no perinatal transmission, 
suppression of viral load to <1,000 copies/mL, delivery 
by intended route and at planned delivery site, and 
receipt of appropriate ART during labor. Despite having 
significantly greater social barriers to care (no family 
support, nondisclosure, substance abuse, mental illness, 
and homelessness), DOT patients achieved a level of 
success similar to that of control patients (63% vs 69%, 
respectively). 
32 
A RCT conducted on 65 HIV infected opiate dependent 
individuals for 24week.  There is difference between 
DOT and treatment as actual. After 12month of DOT 
adherence assessed (86% vs 44%) in DOT and actual 
treatment respectively. Viral load was decreased by 
(71%vs 34%) in DOT and actual treatment respectively. 
However after DOT ended difference in adherence 
diminished by 1month (55% for DOT vs 48% for actual 
treatment). After 3month of DOT discontinuation the 
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difference completely indistinguishable (49% for DOT 
vs 50% for actual treatment).
33
 
5.2.3 Cognitive–behavioral strategies   
Adherence interventions that appear most promising 
include those with cognitive behavioral (CB) strategies 
based on self-efficacy theory and those which include the 
training of pharmacists on adherence strategies. The 
behavioral interventions emphasize self-efficacy; i.e. 
belief in one‟s ability to engage in a behavior as a 
function of choice, effort and persistence. Self-efficacy is 
increased through social modeling opportunities, which 
increases motivation to initiate and maintain new 
behaviors.  Group CB interventions provide a forum for 
modeling skills such as problem-solving, coping, and 
assertiveness, while promoting attitude and behavior 
change through increased self-efficacy.
34
 
CB interventions have been used to enhance patient 
responses to stressors and encourage active coping 
strategies to reduce the deleterious affective and 
behavioral sequelae of HIV infection. Patients obtain 
knowledge, adopt group norms of behavior and share 
concerns with peers, develop illness-management skills, 
improve coping and quality of life, and reduce anxiety 
and depression while increasing medication adherences.
 
35 
On randomized trial conducted by Peltzer and his 
colleagues a total of 152 patients enrolled in the study 76 
in the experimental and 76 in the comparison group. 
Analysis of variance between intervention conditions on 
the adherence information knowledge test scores at pre- 
and post intervention showed a significant increase in the 
intervention compared to the control group at follow-up. 
Adherence motivation and skills did not significantly 
change among the intervention conditions over time. 
Analyses found a significant improvement of ART 
adherence and CD4 count and a significant reduction of 
depression scores over time in both intervention and 
control conditions; however, no significant intervention 
effect between intervention and control conditions was 
found. With higher ART adherence CD4 counts 
increased and depression symptom scores decreased. 
Again, no significant group time interaction effect was 
observed for the total group for either measure 
34 
Two arm RCT conducted by Safren and his colleagues 
on 300 patients comparing CBT to enhance treatment as 
actually only. At the acute outcome assessment (3 
month) those who receive CBT evidenced significantly 
greater improvement in medication adherence and 
depression relative to the comparison group.
36
  
6. CONCLUSIONS  
Adherence to ART is closely tied to virologic, 
immunologic, and clinical outcomes. Small increases in 
adherence can result in significant improvements in these 
outcomes. To help patients benefit fully from ART, 
health care workers need to take time to ask about and 
support medication adherence. Many methods are used 
to assess adherence; in clinical practice, patient self-
report is the most simple and economical.  
There are many ways available for health care workers to 
support and improve medication adherence. Alterable 
factors known to affect adherence, such as patient 
factors, regimen complexity, medication side effects, and 
the therapeutic relationship between patient and provider, 
can be addressed prior to starting therapy and in an 
ongoing way throughout treatment. During therapy, the 
detection of nonadherence is itself a valuable 
accomplishment.  
Improving adherence requires collaborating with the 
patient in an effort to understand and ameliorate 
individual impediments to adherence, generally by 
establishing dedicated time with every patient to educate, 
plan for adherence, and maintain support and 
collaboration throughout the course of treatment. In this 
way, adherence can be regularly assessed, problems can 
be addressed, side effects can be dealt with, medications 
can be simplified or changed if necessary, and adherence 
devices can be used where appropriate. 
7.  FUTURE PERSPECTIVE  
Finally, future research and practice should consider 
intervention approaches that address the live experience 
of individuals in HIV care, which includes adherence 
challenges for those on ART and other life priorities that 
influence treatment adherence. Collaboration with 
patients, in recognition of their often trying life 
circumstances, multidisciplinary involvement with the 
best prospects is crucial for optimal health outcomes. 
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